VERA Stock Analysis: Vera Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.957m USD | 12M Return: 87% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 58.9M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vera Therapeutics, Inc. (NASDAQ: VERA) is a clinical-stage biotechnology company headquartered in Brisbane, California, that develops treatments for immunological diseases. The company was incorporated in 2016, originally as Trucode Gene Repair, Inc., and adopted its current name in April 2020 before completing its IPO on May 14, 2021.
Its lead candidate is atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL). Atacicept is a self-administered subcutaneous injection currently being evaluated for immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. The pipeline also includes MAU868, a human monoclonal antibody for BK viremia infections that has completed Phase 2 trials, and VT-109, a BAFF/APRIL dual-inhibitor BCMA molecule for B cell-mediated autoimmune diseases.
As a clinical-stage biotech, Vera Therapeutics does not yet generate commercial product revenue and its valuation depends on the outcome of ongoing clinical trials and regulatory milestones. IgAN is a leading cause of primary glomerulonephritis worldwide, representing a significant unmet need in nephrology and a competitive area of drug development among biotechnology companies.
- Atacicept pivotal IgAN trial results drive stock movement
- Competition intensifies from Filspari and Tarpeyo in IgAN
- Cash burn raises dilution risk as revenue remains zero
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.52 > 0.02 and ΔFCF/TA -23.37 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.47 > 3% & CFO -293.2m > Net Income -369.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.5m) vs 12m ago 12.26% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -31.70 > 6 (EBIT TTM -357.7m / Interest Expense TTM 11.3m) |
| A: 0.92 (Total Current Assets 615.8m - Total Current Liabilities 45.1m) / Total Assets 621.7m |
| B: -1.42 (Retained Earnings -881.9m / Total Assets 621.7m) |
| C: -0.58 (EBIT TTM -357.7m / Avg Total Assets 616.0m) |
| D: 4.09 (Book Value of Equity 499.7m / Total Liabilities 122.0m) |
| Altman-Z'' = 1.79 = BBB |
As of July 08, 2026, the stock is trading at USD 42.96 with a total of 5,070,734 shares traded. Over the past week, the price has changed by -0.44%, over one month by +35.31%, over three months by +7.40% and over the past year by +87.03%.
Current recommended Stop Loss: 40.10 (which is 6.7% or 1.2 ATR below the current price).
Vera Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy VERA.
- StrongBuy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 78 | 81.6% |
P/B = 5.9185
Revenue TTM = 0.0 USD
EBIT TTM = -357.7m USD
EBITDA TTM = -356.6m USD
Long Term Debt = 75.0m USD (from longTermDebt, last quarter)
Short Term Debt = 549k USD (from shortTermDebt, last fiscal year)
Debt = 76.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.86m
Net Debt = -497.8m USD (calculated: Debt 76.9m - CCE 574.7m)
Enterprise Value = 2.46b USD (2.96b + Debt 76.9m - CCE 574.7m)
Interest Coverage Ratio = -31.70 (Ebit TTM -357.7m / Interest Expense TTM 11.3m)
EV/FCF = -7.56x (Enterprise Value 2.46b / FCF TTM -325.5m)
FCF Yield = -13.24% (FCF TTM -325.5m / Enterprise Value 2.46b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 256k) / Revenue TTM)
Tobins Q-Ratio = 3.96 (Enterprise Value 2.46b / Total Assets 621.7m)
Interest Expense / Debt = 14.67% (Interest Expense 11.3m / Debt 76.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -282.6m (EBIT -357.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.43 (Total Current Assets 615.8m / Total Current Liabilities 59.1m)
Debt / Equity = 0.15 (Debt 76.9m / totalStockholderEquity, last quarter 499.7m)
Debt / EBITDA = 1.40 (negative EBITDA) (Net Debt -497.8m / EBITDA -356.6m)
Debt / FCF = 1.53 (negative FCF - burning cash) (Net Debt -497.8m / FCF TTM -325.5m)
Total Stockholder Equity = 492.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.90% (Net Income -369.0m / Total Assets 621.7m)
RoE = -74.86% (Net Income TTM -369.0m / Total Stockholder Equity 492.8m)
RoCE = -62.98% (EBIT -357.7m / Capital Employed (Equity 492.8m + L.T.Debt 75.0m))
RoIC = -48.96% (negative operating profit) (NOPAT -282.6m / Invested Capital 577.1m)
WACC = 11.09% (E(2.96b)/V(3.03b) * Re(11.08%) + D(76.9m)/V(3.03b) * Rd(14.67%) * (1-Tc(0.21)))
Discount Rate = 11.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 23.50%
[DCF] Fair Price = unknown (Cash Flow -325.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.16 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.71 | Chg30d=-19.98% | Revisions=-57% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-1.64 | Chg30d=-17.62% | Revisions=-57% | Analysts=6
EPS current Year (2026-12-31): EPS=-6.29 | Chg30d=-19.63% | Revisions=-73% | GrowthEPS=-34.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.80 | Chg30d=-24.88% | Revisions=-36% | GrowthEPS=+39.6% | GrowthRev=+566.8%
[Analyst] Revisions Ratio: -74% (up=2, down=22)